Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| RMTI | ROCKWELL MEDICAL, INC. | 2026-04-02 15:04:31 | 0.96 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RMTI | 0001041024 | ROCKWELL MEDICAL, INC. | US7743743004 | 529900Y6YUB5X93MMD77 | 383317208 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 30142 WIXOM ROAD | WIXOM | MI | 48393 | UNITED STATES | US | 8004493353 | 30142 WIXOM ROAD, WIXOM, MI, 48393 | 30142 WIXOM ROAD, WIXOM, MI, 48393 | ROCKWELL MEDICAL TECHNOLOGIES INC | Pharmaceutical industry | 1996 | Stuart Paul | 269 | https://rockwellmed.com/ | 28,688,982 | 39,405,302 | 39,405,302 | Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD). | 2026-04-02 19:55:47 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 28,688,982 | -25,292,404 | -46.8539 | 39,405,302 | 5,348,382 | 15.7042 |
| 2024 | 53,981,386 | -37,067,428 | -40.7116 | 34,056,920 | 4,722,303 | 16.0981 |
| 2023 | 91,048,814 | 79,952,152 | 720.5063 | 29,334,617 | 16,781,944 | 133.6922 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Megan Timmins | Chief Legal Officer, Secretary | 2024 | 412,000 | 0 | 69,500 | 185,400 | 13,800 | 749,889 |
| Jesse Neri | Chief Financial Officer | 2024 | 300,000 | 0 | 46,329 | 135,000 | 12,000 | 539,458 |
| Mark Strobeck | Chief Executive Officer | 2024 | 566,500 | 0 | 139,000 | 453,200 | 13,800 | 1,310,878 |
| Marc Hoffman | Chief Medical Officer | 2023 | 260,226 | 0 | 35,161 | 0 | 159,940 | 486,782 |
| Megan Timmins | Chief Legal Officer, Secretary | 2023 | 412,000 | 0 | 39,065 | 164,800 | 8,944 | 660,288 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 157 |
| 2024 | 244 |
| 2023 | 237 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 69,258,000 | 101,489,000 | 83,612,000 |
| Cost Of Revenue | 57,563,000 | 84,005,000 | 74,908,000 |
| Gross Profit | 11,695,000 | 17,484,000 | 8,704,000 |
| Research And Development Expenses | 0 | 19,000 | 1,107,000 |
| General And Administrative Expenses | 14,032,000 | 14,108,000 | 12,142,000 |
| Operating Expenses | — | — | — |
| Operating Income | -4,691,000 | 608,000 | -6,670,000 |
| Net Income | -5,314,000 | -480,000 | -8,439,000 |
| Earnings Per Share Basic | -0.15 | -0.03 | -0.37 |
| Earnings Per Share Diluted | -0.15 | -0.03 | -0.37 |
| Weighted Average Shares Outstanding Basic | 35,974,231 | 31,058,539 | 23,322,915 |
| Weighted Average Shares Outstanding Diluted | 35,974,231 | 31,058,539 | 23,322,915 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 10,711,000 | 15,662,000 | 8,983,000 |
| Marketable Securities Current | 14,286,000 | 5,940,000 | 1,952,000 |
| Accounts Receivable | 8,143,000 | 8,291,000 | 10,901,000 |
| Inventories | 3,424,000 | 5,778,000 | 5,871,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 38,163,000 | 37,030,000 | 28,770,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 4,629,000 | 5,785,000 | 6,402,000 |
| Other Assets Non Current | 556,000 | 528,000 | 527,000 |
| Total Assets Non Current | 18,982,000 | 22,178,000 | 23,403,000 |
| Total Assets | 57,145,000 | 59,208,000 | 52,173,000 |
| Accounts Payable | 1,999,000 | 2,869,000 | 4,516,000 |
| Deferred Revenue | 0 | 46,000 | 46,000 |
| Short Term Debt | 0 | 0 | 0 |
| Other Liabilities Current | 4,337,000 | 6,275,000 | 7,149,000 |
| Total Liabilities Current | 9,580,000 | 14,091,000 | 16,637,000 |
| Long Term Debt | 8,826,000 | 8,472,000 | 8,293,000 |
| Other Liabilities Non Current | — | 0 | 14,000 |
| Total Liabilities Non Current | 10,584,000 | 12,531,000 | 14,245,000 |
| Total Liabilities | 20,164,000 | 26,622,000 | 30,882,000 |
| Common Stock | 4,000 | 3,000 | 3,000 |
| Retained Earnings | -402,992,000 | -397,678,000 | -397,198,000 |
| Accumulated Other Comprehensive Income | 131,000 | 54,000 | -1,000 |
| Total Shareholders Equity | 36,981,000 | 32,586,000 | 21,291,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 2,192,000 | 2,180,000 | 1,444,000 |
| Share Based Compensation Expense | 1,816,000 | 1,292,000 | 932,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 98,000 | -2,610,000 | 4,642,000 |
| Change In Inventories | -2,779,000 | 332,000 | -1,176,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | -1,410,000 |
| Change In Accounts Payable | -870,000 | -1,647,000 | 463,000 |
| Change In Other Liabilities | -1,679,000 | -1,034,000 | -376,000 |
| Cash From Operating Activities | -659,000 | 4,202,000 | -9,412,000 |
| Purchases Of Marketable Securities | 24,202,000 | 5,858,000 | 5,701,000 |
| Sales Of Marketable Securities | 16,200,000 | 2,003,000 | 15,301,000 |
| Acquisition Of Property Plant And Equipment | 542,000 | 1,011,000 | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -8,544,000 | -4,866,000 | -3,045,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 7,816,000 | 10,181,000 | 14,861,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 4,252,000 | 7,348,000 | 11,342,000 |
| Change In Cash | -4,951,000 | 6,679,000 | -1,119,000 |
| Cash At End Of Period | 10,711,000 | 15,662,000 | 8,983,000 |
| Income Taxes Paid | 0 | — | — |
| Interest Paid | 772,000 | 847,000 | 1,209,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.15 | -0.03 | -0.37 |
| Price To Earnings Ratio | -5.5567 | -68 | -5.1081 |
| Earnings Growth Rate | 400 | -91.8919 | -80.4233 |
| Price Earnings To Growth Ratio | -0.0139 | 0.74 | 0.0635 |
| Book Value Per Share | 1.028 | 1.0492 | 0.9129 |
| Price To Book Ratio | 0.8108 | 1.9444 | 2.0704 |
| Ebitda | -1,998,000 | 2,954,000 | -4,694,000 |
| Enterprise Value | 28,099,521.5385 | 56,169,419.56 | 43,390,309.35 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.2387 | 0.26 | 0.3895 |
| Capital Expenditures | 1,036,000 | 1,563,000 | 5,652,000 |
| Free Cash Flow | -1,695,000 | 2,639,000 | -15,064,000 |
| Return On Equity | -0.1437 | -0.0147 | -0.3964 |
| One Year Beta | 1.2889 | 1.4879 | 2.5654 |
| Three Year Beta | 1.6395 | 1.3949 | 1.3723 |
| Five Year Beta | 1.3601 | 1.267 | 1.2449 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Strobeck Mark | Director, President and CEO | 2026-03-14 | 7,333 | D | 323,493 |
| Chole Timothy | SVP and CCO | 2026-03-14 | 2,444 | D | 122,855 |
| Neri Jesse | SVP and CFO | 2026-03-14 | 2,444 | D | 122,398 |
| TIMMINS MEGAN C. | — | 2026-03-14 | 3,667 | D | 162,408 |
| Hunter Heather | Chief Operating Officer | 2026-03-14 | 2,444 | D | 130,079 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 2025-12-31 | 68,256 | 81,891 | 0.8335 |
| CITADEL ADVISORS LLC | 2025-12-31 | 36,507 | 43,800 | 0.8335 |
| BANK OF AMERICA CORP /DE/ | 2025-12-31 | 478 | 575 | 0.8313 |
| TWO SIGMA SECURITIES, LLC | 2025-12-31 | 28,498 | 34,191 | 0.8335 |
| FMR LLC | 2025-12-31 | 5 | 6 | 0.8333 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD INSTITUTIONAL INDEX FUNDS | 2025-12-31 | Institutional Plus Shares | VITPX | 25,806 | 21,509.3 | 0.0001 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 2025-12-31 | Institutional Shares | VITNX | 25,806 | 21,509.3 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Select Shares | VSTSX | 795,997 | 663,463.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Plus Shares | VSMPX | 795,997 | 663,463.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-12-31 | ETF Shares | VTI | 795,997 | 663,463.5 | 0.0 |